AP2936A - Long term treatment of HIV-infection with TMC278 - Google Patents

Long term treatment of HIV-infection with TMC278

Info

Publication number
AP2936A
AP2936A AP2008004535A AP2008004535A AP2936A AP 2936 A AP2936 A AP 2936A AP 2008004535 A AP2008004535 A AP 2008004535A AP 2008004535 A AP2008004535 A AP 2008004535A AP 2936 A AP2936 A AP 2936A
Authority
AP
ARIPO
Prior art keywords
tmc278
hiv
infection
long term
term treatment
Prior art date
Application number
AP2008004535A
Other languages
English (en)
Other versions
AP2008004535A0 (en
Inventor
Lieven Elvire Colette Baert
Guenter Kraus
Gerben Albert Eleutherius Van T Klooster
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36446113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2936(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of AP2008004535A0 publication Critical patent/AP2008004535A0/xx
Application granted granted Critical
Publication of AP2936A publication Critical patent/AP2936A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2008004535A 2006-01-20 2007-01-19 Long term treatment of HIV-infection with TMC278 AP2936A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06100677 2006-01-20
PCT/EP2007/050516 WO2007082922A2 (fr) 2006-01-20 2007-01-19 Traitement a long terme de l'infection par le vih

Publications (2)

Publication Number Publication Date
AP2008004535A0 AP2008004535A0 (en) 2008-08-31
AP2936A true AP2936A (en) 2014-07-31

Family

ID=36446113

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004535A AP2936A (en) 2006-01-20 2007-01-19 Long term treatment of HIV-infection with TMC278

Country Status (27)

Country Link
US (4) US10953009B2 (fr)
EP (1) EP1981506B3 (fr)
JP (2) JP5754005B2 (fr)
KR (2) KR101501475B1 (fr)
CN (2) CN101370504A (fr)
AP (1) AP2936A (fr)
AR (1) AR059097A1 (fr)
AU (1) AU2007206901B2 (fr)
BR (1) BRPI0707179A2 (fr)
CA (1) CA2636436C (fr)
CY (1) CY1114089T1 (fr)
DK (1) DK1981506T6 (fr)
EA (1) EA014914B1 (fr)
ES (1) ES2414982T7 (fr)
HR (1) HRP20130544T4 (fr)
IL (1) IL192132A (fr)
ME (1) ME01617B (fr)
MY (1) MY150717A (fr)
NZ (1) NZ569347A (fr)
PL (1) PL1981506T6 (fr)
PT (1) PT1981506E (fr)
RS (1) RS52821B2 (fr)
SG (1) SG170073A1 (fr)
SI (1) SI1981506T1 (fr)
TW (1) TWI458483B (fr)
UA (1) UA96436C2 (fr)
WO (1) WO2007082922A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
RS52821B2 (sr) 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
UA97641C2 (xx) 2006-06-23 2012-03-12 Тиботек Фармасьютикелз Лтд. Водна суспензія 4-$$4-$$4-(2-ціаноетеніл)-2,6-диметилфеніл]аміно]-2-піримідиніл]аміно]бензонітрилу (tmc278)$водная суспензия 4-$$4-$$4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила (тмс278)
AU2016219555B2 (en) * 2006-06-23 2017-08-10 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
AU2014200819B2 (en) * 2006-06-23 2016-05-26 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
NZ593950A (en) 2008-12-24 2013-08-30 Janssen R & D Ireland Implantable devices for treating hiv
JP5897465B2 (ja) * 2009-09-22 2016-03-30 ヤンセン・アールアンドデイ・アイルランド Ｈｉｖ感染の処置及び予防
RU2593790C2 (ru) 2009-12-21 2016-08-10 Янссен Сайенсиз Айрлэнд Юси Разлагаемый удаляемый имплантат для непрерывного высвобождения активного соединения
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US9266824B2 (en) 2014-01-13 2016-02-23 Warsaw Orthopedic, Inc. Methods and compositions for making an amino acid triisocyanate
WO2017084973A1 (fr) * 2015-11-16 2017-05-26 Evonik Röhm Gmbh Solution injectable comprenant un inhibiteur de transcriptase inverse non nucléosidique et du poly(lactide-co-glycolide)
US20190163877A1 (en) * 2017-11-27 2019-05-30 International Business Machines Corporation Decision support for effective long-term drug therapy
WO2022079739A1 (fr) 2020-10-14 2022-04-21 Cipla Limited Compositions à dose fixe de cabotégravir et de rilpivirine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021001A1 (fr) * 2003-09-03 2005-03-10 Tibotec Pharmaceuticals Ltd. Combinaisons d'une pyrimidine renfermant nnrti avec des inhibiteurs de rt

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
DE60020382T2 (de) 1999-09-21 2006-01-26 Skyepharma Canada Inc., Verdun Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
GEP20043285B (en) 2000-03-30 2004-07-26 Bristol Myers Squibb Co Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2002364701B8 (en) 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
US6568805B1 (en) * 2001-11-26 2003-05-27 Dan L. Dietz Trust Magnetic buckle for eyeglasses
AU2003210659A1 (en) * 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
JP2006508134A (ja) 2002-11-08 2006-03-09 グラクソ　グループ　リミテッド 医薬組成物
CA2506244C (fr) 2002-11-18 2012-10-30 Phoenix Pharmacologics, Inc. Methodes d'inhibition d'une replication virale in vivo
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
CA2515679A1 (fr) 2003-02-21 2004-09-02 Tripep Ab Derive du glycinamide destine a inhiber la replication du vih
PT1632232E (pt) * 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
WO2006024668A1 (fr) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7910577B2 (en) 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
RS52821B2 (sr) 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
UA97641C2 (xx) 2006-06-23 2012-03-12 Тиботек Фармасьютикелз Лтд. Водна суспензія 4-$$4-$$4-(2-ціаноетеніл)-2,6-диметилфеніл]аміно]-2-піримідиніл]аміно]бензонітрилу (tmc278)$водная суспензия 4-$$4-$$4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила (тмс278)
CA2693044C (fr) 2007-07-12 2017-03-14 Tibotec Pharmaceuticals Forme cristalline de of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021001A1 (fr) * 2003-09-03 2005-03-10 Tibotec Pharmaceuticals Ltd. Combinaisons d'une pyrimidine renfermant nnrti avec des inhibiteurs de rt

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUSMAN E.: "RETROVIRUSES AND OPPORTUNISTIC INFECTIONS", IDRUGS, CURRENT DRUGS LTD., GB, vol. 8, no. 4, 2005, pages 299-302, XP008051947, ISSN: 1369-7056, page 300, column 2, paragraph 2 *

Also Published As

Publication number Publication date
JP2009526758A (ja) 2009-07-23
DK1981506T6 (da) 2021-06-14
NZ569347A (en) 2011-07-29
HRP20130544T4 (hr) 2021-08-20
AP2008004535A0 (en) 2008-08-31
ES2414982T3 (es) 2013-07-23
HK1125828A1 (en) 2009-08-21
IL192132A (en) 2014-05-28
KR20080085194A (ko) 2008-09-23
PL1981506T6 (pl) 2021-07-12
JP5754005B2 (ja) 2015-07-22
CN101370504A (zh) 2009-02-18
PL1981506T3 (pl) 2013-08-30
WO2007082922A8 (fr) 2008-01-03
CN103877091A (zh) 2014-06-25
CA2636436A1 (fr) 2007-07-26
EA014914B1 (ru) 2011-02-28
US20210177843A1 (en) 2021-06-17
SI1981506T1 (sl) 2013-08-30
US20110275654A1 (en) 2011-11-10
HRP20130544T1 (en) 2013-07-31
SG170073A1 (en) 2011-04-29
WO2007082922A3 (fr) 2007-09-20
KR20140141699A (ko) 2014-12-10
RS52821B (sr) 2013-10-31
RS52821B2 (sr) 2021-07-30
CA2636436C (fr) 2014-04-01
CY1114089T1 (el) 2016-07-27
BRPI0707179A2 (pt) 2011-04-26
ES2414982T7 (es) 2021-11-05
EP1981506B1 (fr) 2013-03-27
DK1981506T3 (da) 2013-06-24
AR059097A1 (es) 2008-03-12
US10953009B2 (en) 2021-03-23
AU2007206901B2 (en) 2013-01-31
KR101501475B1 (ko) 2015-03-19
USRE50189E1 (en) 2024-10-29
EA200870183A1 (ru) 2009-12-30
EP1981506B3 (fr) 2021-06-09
TW200806295A (en) 2008-02-01
UA96436C2 (ru) 2011-11-10
EP1981506A2 (fr) 2008-10-22
JP2013100338A (ja) 2013-05-23
AU2007206901A1 (en) 2007-07-26
KR101562943B1 (ko) 2015-10-23
IL192132A0 (en) 2009-08-03
US20240226099A1 (en) 2024-07-11
ME01617B (me) 2014-09-20
MY150717A (en) 2014-02-28
JP5836983B2 (ja) 2015-12-24
TWI458483B (zh) 2014-11-01
PT1981506E (pt) 2013-06-25
WO2007082922A2 (fr) 2007-07-26

Similar Documents

Publication Publication Date Title
AP2936A (en) Long term treatment of HIV-infection with TMC278
ZA200708454B (en) Prevention of HIV-infection with TMC278
HUE037639T2 (hu) Pimavanszerin együttes beadása más szerekkel
GB0610867D0 (en) Treatment of pain
IL193748A0 (en) Treatment of pain
GB0702931D0 (en) Skin application
GB0909297D0 (en) Composition for the treatment of skin conditions
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
PL1945243T3 (pl) Zastosowanie kalcytoniny w leczeniu rzs
GB0506835D0 (en) Therapeutic use of nefopam
DK2392335T3 (en) Use of 24-norUDCA
GB0610868D0 (en) Treatment of pain
GB0515703D0 (en) Therapeutic use of nefopam
GB0602857D0 (en) The treatment of sialorrhoea
GB0616450D0 (en) Treatment of pain
GB0601091D0 (en) The Treatment Of Ocular Conditions
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0602858D0 (en) The treatment of sialorrhoea
HU0700758D0 (en) The basic of biocomputer and the possible realization thereof
GB0625602D0 (en) Treatment of sialorrhoea
GB0521338D0 (en) Full length body shower
TJ20050863A (en) The way of narcotism treatment
GB0722338D0 (en) Novel use and treatment
GB0603076D0 (en) The treatment of hyperhidrosis
GB0603075D0 (en) The treatment of hyperhidrosis